Sangamo exec granted 225,000 stock options
Sangamo Therapeutics reported that Head of Research & Technology Gregory D. Davis received a new stock option grant.
Rhea-AI Filing Summary
Sangamo Therapeutics reported that Head of Research & Technology Gregory D. Davis received a new stock option grant. The award covers 225,000 stock options for common shares at an exercise price of $0.2601 per share, expiring on March 31, 2036.
One-quarter of the options will vest on the first anniversary of the grant, with the remaining options vesting in 24 equal monthly installments, contingent on his continued service under the company’s 2018 equity incentive plan. After this grant, he holds 225,000 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 225,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
exercise price financial
Continuous Service financial
2018 EIP financial
vest financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Sangamo Therapeutics (SGMO) report for Gregory D. Davis?
How many Sangamo Therapeutics (SGMO) stock options were granted to Gregory D. Davis?
What is the exercise price of Gregory D. Davis’s new Sangamo (SGMO) stock options?
When do the newly granted Sangamo (SGMO) options to Gregory D. Davis expire?
How do Gregory D. Davis’s Sangamo (SGMO) options vest over time?
Is Gregory D. Davis’s Sangamo (SGMO) stock option grant an open-market purchase?
AI-generated analysis. How Rhea-AI works. Not financial advice.